Description

BPC-157 — Research Peptide

Name: ZentraBio™ - BPC-157 - 10 mg - Achieve Weightloss
Price: 36.00 EUR
Availability: InStock

Product Description

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, derived from a protective protein fragment identified in human gastric juice. It is studied as a cytoprotective, pro-repair signaling peptide with broad preclinical literature spanning tendon, ligament, muscle, gastrointestinal, vascular, and neurologic injury models.

Unlike many experimental peptides that target a single receptor or pathway, BPC-157 acts as a multi-pathway biological signaling molecule, influencing:

Tissue repair and regeneration
Nitric oxide signaling
Angiogenesis and vascular function
Growth factor expression
Immune system regulation
Mitochondrial function and energy metabolism

While the majority of research remains preclinical (animal models and cell studies), the peptide has generated significant scientific interest due to its unique ability to accelerate healing across multiple tissues simultaneously.

Study overview
https://pubmed.ncbi.nlm.nih.gov/28035768/

Key Research Characteristics

Compound: BPC-157
Type: Synthetic pentadecapeptide
Sequence: GEPPPGKPADDAGLV
Primary research domains: cytoprotection, tissue regeneration, nitric-oxide signaling, vascular biology
Evidence base: predominantly animal and in-vitro research

Research summary
https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/

Research Context Exposure Ranges (Educational Only)

⚠️ Not medical guidance. The ranges below reflect experimental discussions in literature and laboratory forums.

Experimental daily exposure ranges discussed in research contexts

Exploratory range: ~200–300 mcg/day
Common research-use range: ~500 mcg/day
Upper experimental range (reported, not established): ~1,000 mcg/day

Experimental duration patterns

Typical research windows discussed: ~4–6 weeks
Recovery-model exposure discussions: ~4–8 weeks

These patterns are anecdotal conventions discussed in experimental communities and not validated clinical standards.

Pharmacokinetic research
https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/

Evidence Interpretation

Preclinical evidence

Tendon repair and fibroblast migration
Vascular recovery and nitric oxide signaling
Cytoprotective effects in gastrointestinal tissue
Neurological experimental models

Human evidence

Small retrospective knee study
Registered Phase I oral pharmacokinetic trial

Human study
https://pubmed.ncbi.nlm.nih.gov/34324435/

Clinical trial registry
https://clinicaltrials.gov/study/NCT02637284

Expanded Research Overview

(Educational reference section — long-form scientific background)

Scientific Background

BPC-157 was developed from a gastric protein fragment and has been explored in experimental models as a stable gastric pentadecapeptide with pleiotropic effects on wound healing, vascular recovery, and cytoprotection.

Reviews from Sikiric and colleagues summarize a large body of rat and cell-model data, but those reviews do not substitute for robust human trials.

Literature review
https://pubmed.ncbi.nlm.nih.gov/23755725/

A key point from the better literature is that BPC-157 is most defensibly framed as a research peptide with unusually broad preclinical activity, not as a clinically established cure-all.

Evidence review
https://pubmed.ncbi.nlm.nih.gov/40789979/

Molecular Structure

Defined pentadecapeptide

Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val

One-letter sequence

GEPPPGKPADDAGLV

Study
https://pubmed.ncbi.nlm.nih.gov/28035768/

Mechanistic Profile

Nitric Oxide Signaling

BPC-157 has been shown in experimental systems to modulate vasomotor tone through nitric-oxide-dependent mechanisms involving the Src–Cav-1–eNOS pathway.

This supports the hypothesis that the peptide may regulate vascular tone during tissue injury and repair.

Mechanistic study
https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/